Patent EP0572287A2 successfully refreshed from Google Patents.
EP0572287A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Use of cyclic double-stranded oligonucleotides containing the binding site for a transcription factor for inhibiting gene expression
Assignee: Merck Biodevelopment SAS
•
Filing: 1993-01-22
•
Granted: —
•
Expires: 2013-01-22
Abstract
Abstract The present invention concerns the use of a double-stranded closed oligonucleotide containing a binding site for a given transcription factor, e.g. HNF-1 factor, for inhibiting the expression of a given gene under the control of said transcription factor, e.g. liver-specific genes coding for fibrinogen, transthyretin, apolipoprotein B or the pre-S₁ gene of hepatitis B virus. Particularly preferred oligonucleotides are the ones containing the sequence 5'GTTANT3', wherein N can be any of A,T,C or G.
Inventors
- 👤 Marta Blumenfeld
- 👤 Catherine Clusel
- 👤 Nathalie Enjolras
- 👤 Edgarto Ugarte Romero
- 👤 Marc Vasseur
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-08 10:57
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; A; A61; A61K; A61K31/00; A61K31/70; A61P; A61P31/00; A61P31/12; A61P35/00; A61P37/00; C12N2310/00; C12N2310/10; C12N2310/13; C12N2310/50; C12N2310/53
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
36 words
1- Use of a compound consisting of a double-stranded closed oligonucleotide containing a binding site for a given transcription factor, for inhibiting the expression of a given gene expressed under the control of said transcription factor.
Claim 2
Dependent Claim
36 words
1- Use of a compound consisting of a double-stranded closed oligonucleotide containing a binding site for a given transcription factor, for inhibiting the expression of a given gene expressed under the control of said transcription factor.
Claim 3
Dependent Claim
32 words
2- Use of a compound according to claim 1 for inhibiting the transcription of a given gene under the control of a promotor or enhancer elements which bind to said transcription factor.
Claim 4
Dependent Claim
47 words
3- Use of a compound consisting of a double-stranded closed oligonucleotide containing a binding site for transcription factor controlling the expression of a given gene of pathological interest, for preparing a pharmaceutical composition for the therapeutical treatment of pathology in which the said given gene is involved.
Claim 5
Dependent Claim
47 words
3- Use of a compound consisting of a double-stranded closed oligonucleotide containing a binding site for transcription factor controlling the expression of a given gene of pathological interest, for preparing a pharmaceutical composition for the therapeutical treatment of pathology in which the said given gene is involved.
Claim 6
Dependent Claim
21 words
4- Use of a compound according to any one of claims 1 to 3 wherein said transcription factor is HNF-1 factor.
Claim 7
Dependent Claim
23 words
5- Use of a compound according to any one of claims 1 to 4 wherein the said given gene is a liver-specific gene.
Claim 8
Dependent Claim
30 words
6- Use of a compound according to claim 5 wherein the said given gene is a gene coding for fibrinogen, transthyretin, apolipoprotein B or pre-S1 gene of hepatitis B virus.
Claim 9
Dependent Claim
41 words
7- Use of a compound as in claims 4 to 9 wherein the said compound consists of a double-stranded closed oligonucleotide containing at least the sequence 5'GTTANT 3', and its complementary strand, which is part of the pseudo-palindromic HNF-1 binding sequence.
Claim 10
Dependent Claim
32 words
8- Use of a compound according as in claim 4 when the said compound consists of a rouble-stranded closed oligonucleotide containing a binding site for the transcription factor HNF-1 among the followings:
Claim 11
Dependent Claim
25 words
9- Use of a compound according to any one of claims 4 to 8 , wherein the closed oligonucleotide is GT-56c represented in table 1.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.